A detailed history of W Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, W Advisors, LLC holds 18,835 shares of BMY stock, worth $1.09 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
18,835
Previous 19,986 5.76%
Holding current value
$1.09 Million
Previous $830,000 17.35%
% of portfolio
0.6%
Previous 0.55%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$39.66 - $51.75 $45,648 - $59,564
-1,151 Reduced 5.76%
18,835 $974,000
Q2 2024

Aug 06, 2024

BUY
$40.25 - $52.99 $7,084 - $9,326
176 Added 0.89%
19,986 $830,000
Q1 2024

Apr 25, 2024

BUY
$47.98 - $54.4 $3,502 - $3,971
73 Added 0.37%
19,810 $1.07 Million
Q4 2023

Feb 06, 2024

BUY
$48.48 - $57.85 $6,835 - $8,156
141 Added 0.72%
19,737 $1.01 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $124,868 - $139,622
-2,157 Reduced 9.92%
19,596 $1.14 Million
Q2 2023

Aug 03, 2023

BUY
$63.71 - $70.74 $8,791 - $9,762
138 Added 0.64%
21,753 $1.39 Million
Q1 2023

Aug 07, 2023

SELL
$65.71 - $74.53 $6,768 - $7,676
-103 Reduced 0.47%
21,650 $1.5 Million
Q4 2022

Feb 06, 2023

SELL
$68.48 - $81.09 $167,228 - $198,021
-2,442 Reduced 10.15%
21,615 $1.55 Million
Q3 2022

Oct 24, 2022

SELL
$0.13 - $76.84 $27 - $16,366
-213 Reduced 0.88%
24,057 $1.71 Million
Q2 2022

Aug 26, 2022

BUY
$72.62 - $79.98 $10,021 - $11,037
138 Added 0.57%
24,270 $1.87 Million
Q1 2022

Aug 26, 2022

BUY
$61.48 - $73.72 $63,693 - $76,373
1,036 Added 4.49%
24,132 $1.76 Million
Q4 2021

Aug 15, 2022

BUY
$53.63 - $62.52 $1.24 Million - $1.44 Million
23,096 New
23,096 $1.44 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track W Advisors, LLC Portfolio

Follow W Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of W Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on W Advisors, LLC with notifications on news.